Kinase inhibitors are being highly publicized as a potential treatment for alopecia areata (AA). Janus kinase (JAK) inhibitors are being researched for the pathogenesis of alopecia areata, thus revealing that autoreactive cytotoxic T cells are important in the pathway that involves JAK.
Companies in the kinase inhibitors market are collaborating with researchers to carry out single-arm clinical trials, thus revealing the potential of oral JAK inhibitors as therapeutic agents for AA. Potential outcomes suggest that oral JAK inhibitors are effective and substantially tolerable to cases of moderate to severe AA. Researchers in the kinase inhibitors market are increasing efforts to conduct placebo?controlled clinical trials in order to confirm its efficacy and long-term safety.
Recent advancements are being made in anti-angiogenesis receptor tyrosine kinase inhibitors for the treatment of cancer. Angiogenesis is gaining the attention of healthcare companies to develop therapeutic targets for malignant tumors. Companies are achieving success by targeting angiogenesis in various carcinomas.
The kinase inhibitors market is expected to expand at a modest CAGR of ~4% during the forecast period. However, innovations such as AI are transforming the market for kinase inhibitors. For instance, the U.S. biotechnology startup Insilico Medicine revealed its deep learning system that is capable of identifying potential treatments for fibrosis with the help of DDR1 (Discoidin Domain Receptor 1) kinase inhibitors.
AI is entering the kinase inhibitors market. Hence, companies should collaborate with biotechnology startups that are capable of integrating target identification with small molecule discovery through AI. Companies are increasing their efficacy in molecular modeling to accelerate drug discovery for fibrosis and other diseases.
Healthcare companies are capitalizing on generative adversarial networks (GANs) to generate novel molecular structures with specified properties. Likewise, deep learning is enabling companies with rapid identification of potent DDR1 kinase inhibitors. Thus, companies are improving their production capabilities to develop a novel drug pipeline of treatment of fibrosis with the help of AI.
Novel assays and profiling techniques are helping companies to develop improved kinase inhibitors for drug development. Discovery of new kinase inhibitors is anticipated to improve biochemical, cellular, and in vivo assays that could offer new therapeutic targets. This is important since oncology is the focus of healthcare providers in the kinase inhibitors space, and research in this field of study is projected to grow exponentially.
Companies in the kinase inhibitors market are increasing R&D to gain expertise in cell signaling for the development of new drugs. The kinase inhibitors market is continuing to grow since the market is largely consolidated with major players accounting to ~68% of the market share. However, developing novel kinase inhibitors poses as a challenge for manufacturers. Hence, manufacturers are collaborating with researchers to acquire a decision-based understanding of kinase biology, cell signaling, and its outcome in various diseases. They are increasing efforts to gain information on biochemical and biophysical assays to examine the potency and selectivity of kinase inhibitors.
Tyrosine kinase inhibitors are being increasingly used for the treatment of autoimmune and inflammatory skin diseases. This is evident since inflammatory diseases application segment is estimated to account for a significant share of the kinase inhibitors market. The global kinase inhibitors market is estimated to reach a value of ~US$ 64.9 Bn by the end of 2027. Owing to excellent multiple signaling processes and disease pathogenesis of tyrosine kinase inhibitors, companies are tapping into incremental opportunities, since these inhibitors serve as novel therapeutic agents for inflammatory and other diseases.
Small molecule tyrosine kinase inhibitors are capable of acquiring pharmacological control in malignant processes, and autoimmune and immune-mediated diseases. Companies in the kinase inhibitors market are expanding their product portfolio in tyrosine kinase inhibitors for the treatment of rheumatoid arthritis. They are increasing efforts to gain approval from health commissions for JAK inhibitors, owing to their effectiveness in the treatment of rheumatoid arthritis.
Analysts’ Viewpoint
Developers are designing immune-modulatory agents for single and combination therapies for the treatment of inflammatory and central nervous system disorders. Companies in the kinase inhibitors market are developing cell assays, since they are more advantageous than biochemical assays, owing to the former’s representation in physiological situation.
Multikinase inhibitors are projected for aggressive growth in the market. However, the effectiveness of multikinase inhibitors is short-lived in RET fusion-positive non-small cell lung cancer. Hence, companies should increase research to find a combination of therapeutics to prevent resistance of multikinase inhibitors toward RET-driven cancer. Companies should tap into opportunities in North America and Asia Pacific, since the kinase inhibitors market in these regions is projected for aggressive growth during the forecast period.
Kinase Inhibitors Market – Segmentation
TMR’s study on the global kinase inhibitors market includes information divided into: type, application, distribution channel, and region. Changing industry trends and other crucial market dynamics associated with these segments of the global kinase inhibitors market have been discussed in detail.
|
Type
|
|
|
|
|
|
|
|
|
|
|
Kinase inhibitors market is estimated to reach a value of ~US$ 64.9 Bn by the end of 2027
Kinase inhibitors market is projected to expand at a CAGR of ~4% from 2019 to 2027
Kinase inhibitors market is driven by increase in incidence of cancer patients among population
North America accounted for major share of the global kinase inhibitors market, owing to introduction of new drugs
Key players in the global kinase inhibitors market include Novartis AG, Pfizer, Johnson & Johnson, AstraZeneca, Bristol-Myers Squibb
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary : Global Kinase Inhibitors Market
4. Market Overview
4.1. Introduction & Overview
4.2. Market Dynamics
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.3. Porter’s Five Forces Analysis
4.4. Global Kinase Inhibitors Market Analysis and Forecast, 2017–2027
5. Market Outlook
5.1. Pipeline Analysis
5.2. Brand Analysis
5.3. Recent Developments In Kinase Inhibitors Research
6. Global Kinase Inhibitors Market Analysis and Forecasts, by Type
6.1. Introduction & Definition
6.2. Global Kinase Inhibitors Market Value (US$ Mn) Forecast, by Type, 2017–2027
6.2.1. Non-receptor Tyrosine Kinase Inhibitors
6.2.1.1. Bruton's Tyrosine Kinase (BTK) Inhibitors
6.2.1.2. BCR-ABL
6.2.1.3. Janus Kinase (JAK) Inhibitor
6.2.1.4. Mesenchymal Epithelial Transition Growth Factor (c-MET)
6.2.1.5. Spleen Tyrosine Kinase (SYK) Inhibitors
6.2.1.6. Others
6.2.2. Receptor Tyrosine Kinase Inhibitors
6.2.2.1. VEGFR
6.2.2.2. PDGFR
6.2.2.3. EGFR
6.2.2.4. ALK
6.2.2.5. HER2
6.2.2.6. Others
6.2.3. Multikinase inhibitors
6.2.4. Serine/Threonine Kinase Inhibitors
6.2.5. Protein Kinase C Inhibitors
6.2.6. RHO Kinase Inhibitors
6.2.7. Others
6.3. Global Kinase Inhibitors Market Attractiveness, by Type
7. Global Kinase Inhibitors Market Analysis and Forecasts, by Application
7.1. Introduction & Definition
7.2. Global Kinase Inhibitors Market Value (US$) Forecast, by Application, 2017–2027
7.2.1. Oncology
7.2.1.1. Lung Cancer
7.2.1.2. Renal cell cancer
7.2.1.3. Breast Cancer
7.2.1.4. Others
7.2.2. Inflammatory Diseases
7.2.3. Others
7.3. Global Kinase Inhibitors Market Attractiveness, by Application
8. Global Kinase Inhibitors Market Analysis and Forecasts, by Distribution Channel
8.1. Introduction & Definition
8.2. Global Kinase Inhibitors Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
8.2.1. Hospital Pharmacies
8.2.2. Independent Pharmacies
8.2.3. Online Pharmacies
8.3. Global Kinase Inhibitors Market Attractiveness, by Distribution Channel
9. Global Kinase Inhibitors Market Analysis and Forecasts, by Region
9.1. Key Findings
9.2. Global Kinase Inhibitors Market Value (US$ Mn) Forecast, by Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Global Kinase Inhibitors Market Attractiveness, by Region
10. North America Kinase Inhibitors Market Analysis and Forecast
10.1. Introduction
10.2. North America Kinase Inhibitors Market Value (US$ Mn) Forecast, by Type, 2017–2027
10.2.1. Non-receptor Tyrosine Kinase Inhibitors
10.2.1.1. Bruton's Tyrosine Kinase (BTK) Inhibitors
10.2.1.2. BCR-ABL
10.2.1.3. Janus Kinase (JAK) Inhibitor
10.2.1.4. Mesenchymal Epithelial Transition Growth Factor (c-MET)
10.2.1.5. Spleen Tyrosine Kinase (SYK) Inhibitors
10.2.1.6. Others
10.2.2. Receptor Tyrosine Kinase Inhibitors
10.2.2.1. VEGFR
10.2.2.2. PDGFR
10.2.2.3. EGFR
10.2.2.4. ALK
10.2.2.5. HER2
10.2.2.6. Others
10.2.3. Multikinase inhibitors
10.2.4. Serine/Threonine Kinase Inhibitors
10.2.5. Protein Kinase C Inhibitors
10.2.6. RHO Kinase Inhibitors
10.2.7. Others
10.3. North America Kinase Inhibitors Market Value (US$ Mn) Forecast, by Application, 2017–2027
10.3.1. Oncology
10.3.1.1. Lung Cancer
10.3.1.2. Renal cell cancer
10.3.1.3. Breast Cancer
10.3.1.4. Others
10.3.2. Inflammatory Diseases
10.3.3. Others
10.4. North America Kinase Inhibitors Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
10.4.1. Hospital Pharmacies
10.4.2. Independent Pharmacies
10.4.3. Online Pharmacies
10.5. North America Kinase Inhibitors Market Value (US$ Mn) Forecast, by Country, 2017–2027
10.5.1. U.S.
10.5.2. Canada
10.6. North America Kinase Inhibitors Market Attractiveness Analysis
10.6.1. By Type
10.6.2. By Application
10.6.3. By Distribution Channel
10.6.4. By Country
11. Europe Kinase Inhibitors Market Analysis and Forecast
11.1. Introduction
11.2. Europe Kinase Inhibitors Market Value (US$ Mn) Forecast, by Type, 2017–2027
11.2.1. Non-receptor Tyrosine Kinase Inhibitors
11.2.1.1. Bruton's Tyrosine Kinase (BTK) Inhibitors
11.2.1.2. BCR-ABL
11.2.1.3. Janus Kinase (JAK) Inhibitor
11.2.1.4. Mesenchymal Epithelial Transition Growth Factor (c-MET)
11.2.1.5. Spleen Tyrosine Kinase (SYK) Inhibitors
11.2.1.6. Others
11.2.2. Receptor Tyrosine Kinase Inhibitors
11.2.2.1. VEGFR
11.2.2.2. PDGFR
11.2.2.3. EGFR
11.2.2.4. ALK
11.2.2.5. HER2
11.2.2.6. Others
11.2.3. Multikinase inhibitors
11.2.4. Serine/Threonine Kinase Inhibitors
11.2.5. Protein Kinase C Inhibitors
11.2.6. RHO Kinase Inhibitors
11.2.7. Others
11.3. Europe Kinase Inhibitors Market Value (US$ Mn) Forecast, by Application, 2017–2027
11.3.1. Oncology
11.3.1.1. Lung Cancer
11.3.1.2. Renal cell cancer
11.3.1.3. Breast Cancer
11.3.1.4. Others
11.3.2. Inflammatory Diseases
11.3.3. Others
11.4. Europe Kinase Inhibitors Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
11.4.1. Hospital Pharmacies
11.4.2. Independent Pharmacies
11.4.3. Online Pharmacies
11.5. Europe Kinase Inhibitors Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Spain
11.5.5. Italy
11.5.6. Rest of Europe
11.6. Europe Kinase Inhibitors Market Attractiveness Analysis
11.6.1. By Type
11.6.2. By Application
11.6.3. By Distribution Channel
11.6.4. By Country/Sub-region
12. Asia Pacific Kinase Inhibitors Market Analysis and Forecast
12.1. Introduction
12.2. Asia Pacific Kinase Inhibitors Market Value (US$ Mn) Forecast, by Type, 2017–2027
12.2.1. Non-receptor Tyrosine Kinase Inhibitors
12.2.1.1. Bruton's Tyrosine Kinase (BTK) Inhibitors
12.2.1.2. BCR-ABL
12.2.1.3. Janus Kinase (JAK) Inhibitor
12.2.1.4. Mesenchymal Epithelial Transition Growth Factor (c-MET)
12.2.1.5. Spleen Tyrosine Kinase (SYK) Inhibitors
12.2.1.6. Others
12.2.2. Receptor Tyrosine Kinase Inhibitors
12.2.2.1. VEGFR
12.2.2.2. PDGFR
12.2.2.3. EGFR
12.2.2.4. ALK
12.2.2.5. HER2
12.2.2.6. Others
12.2.3. Multikinase inhibitors
12.2.4. Serine/Threonine Kinase Inhibitors
12.2.5. Protein Kinase C Inhibitors
12.2.6. RHO Kinase Inhibitors
12.2.7. Others
12.3. Asia Pacific Kinase Inhibitors Market Value (US$ Mn) Forecast, by Application, 2017–2027
12.3.1. Oncology
12.3.1.1. Lung Cancer
12.3.1.2. Renal cell cancer
12.3.1.3. Breast Cancer
12.3.1.4. Others
12.3.2. Inflammatory Diseases
12.3.3. Others
12.4. Asia Pacific Kinase Inhibitors Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
12.4.1. Hospital Pharmacies
12.4.2. Independent Pharmacies
12.4.3. Online Pharmacies
12.5. Asia Pacific Kinase Inhibitors Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Asia Pacific Kinase Inhibitors Market Attractiveness Analysis
12.6.1. By Type
12.6.2. By Application
12.6.3. By Distribution Channel
12.6.4. By Country/Sub-region
13. Latin America Kinase Inhibitors Market Analysis and Forecast
13.1. Introduction
13.2. Latin America Kinase Inhibitors Market Value (US$ Mn) Forecast, by Type, 2017–2027
13.2.1. Non-receptor Tyrosine Kinase Inhibitors
13.2.1.1. Bruton's Tyrosine Kinase (BTK) Inhibitors
13.2.1.2. BCR-ABL
13.2.1.3. Janus Kinase (JAK) Inhibitor
13.2.1.4. Mesenchymal Epithelial Transition Growth Factor (c-MET)
13.2.1.5. Spleen Tyrosine Kinase (SYK) Inhibitors
13.2.1.6. Others
13.2.2. Receptor Tyrosine Kinase Inhibitors
13.2.2.1. VEGFR
13.2.2.2. PDGFR
13.2.2.3. EGFR
13.2.2.4. ALK
13.2.2.5. HER2
13.2.2.6. Others
13.2.3. Multikinase inhibitors
13.2.4. Serine/Threonine Kinase Inhibitors
13.2.5. Protein Kinase C Inhibitors
13.2.6. RHO Kinase Inhibitors
13.2.7. Others
13.3. Latin America Kinase Inhibitors Market Value (US$ Mn) Forecast, by Application, 2017–2027
13.3.1. Oncology
13.3.1.1. Lung Cancer
13.3.1.2. Renal cell cancer
13.3.1.3. Breast Cancer
13.3.1.4. Others
13.3.2. Inflammatory Diseases
13.3.3. Others
13.4. Latin America Kinase Inhibitors Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
13.4.1. Hospital Pharmacies
13.4.2. Independent Pharmacies
13.4.3. Online Pharmacies
13.5. Latin America Kinase Inhibitors Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Latin America Kinase Inhibitors Market Attractiveness Analysis
13.6.1. By Type
13.6.2. By Application
13.6.3. By Distribution Channel
13.6.4. By Country/Sub-region
14. Middle East & Africa Kinase Inhibitors Market Analysis and Forecast
14.1. Introduction
14.2. Middle East & Africa Kinase Inhibitors Market Value (US$ Mn) Forecast, by Type, 2017–2027
14.2.1. Non-receptor Tyrosine Kinase Inhibitors
14.2.1.1. Bruton's Tyrosine Kinase (BTK) Inhibitors
14.2.1.2. BCR-ABL
14.2.1.3. Janus Kinase (JAK) Inhibitor
14.2.1.4. Mesenchymal Epithelial Transition Growth Factor (c-MET)
14.2.1.5. Spleen Tyrosine Kinase (SYK) Inhibitors
14.2.1.6. Others
14.2.2. Receptor Tyrosine Kinase Inhibitors
14.2.2.1. VEGFR
14.2.2.2. PDGFR
14.2.2.3. EGFR
14.2.2.4. ALK
14.2.2.5. HER2
14.2.2.6. Others
14.2.3. Multikinase inhibitors
14.2.4. Serine/Threonine Kinase Inhibitors
14.2.5. Protein Kinase C Inhibitors
14.2.6. RHO Kinase Inhibitors
14.2.7. Others
14.3. Middle East & Africa Kinase Inhibitors Market Value (US$ Mn) Forecast, by Application, 2017–2027
14.3.1. Oncology
14.3.1.1. Lung Cancer
14.3.1.2. Renal cell cancer
14.3.1.3. Breast Cancer
14.3.1.4. Others
14.3.2. Inflammatory Diseases
14.3.3. Others
14.4. Middle East & Africa Kinase Inhibitors Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
14.4.1. Hospital Pharmacies
14.4.2. Independent Pharmacies
14.4.3. Online Pharmacies
14.5. Middle East & Africa Kinase Inhibitors Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Israel
14.5.4. Rest of Middle East & Africa
14.6. Middle East & Africa Kinase Inhibitors Market Attractiveness Analysis
14.6.1. By Type
14.6.2. By Application
14.6.3. By Distribution Channel
14.6.4. By Country/Sub-region
15. Competition Landscape
15.1. Competition Matrix
15.2. Market Share Analysis, by Company (2018)
15.3. Company Profiles
15.3.1. Boehringer Ingelheim International GmbH
15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.1.2. Company Financials
15.3.1.3. Growth Strategies
15.3.1.4. SWOT Analysis
15.3.2. Novartis AG
15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.2.2. Company Financials
15.3.2.3. Growth Strategies
15.3.2.4. SWOT Analysis
15.3.3. AstraZeneca plc
15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.3.2. Company Financials
15.3.3.3. Growth Strategies
15.3.3.4. SWOT Analysis
15.3.4. Pfizer, Inc.
15.3.4.1. Company Overview (HQ, Business Segments)
15.3.4.2. Company Financials
15.3.4.3. Growth Strategies
15.3.4.4. SWOT Analysis
15.3.5. F. Hoffmann-La Roche Ltd
15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.5.2. Company Financials
15.3.5.3. Growth Strategies
15.3.5.4. SWOT Analysis
15.3.6. Bristol-Myers Squibb Company
15.3.6.1. Company Overview (HQ, Business Segments)
15.3.6.2. Company Financials
15.3.6.3. Growth Strategies
15.3.6.4. SWOT Analysis
15.3.7. Johnson & Johnson
15.3.7.1. Company Overview (HQ, Business Segments)
15.3.7.2. Company Financials
15.3.7.3. Growth Strategies
15.3.7.4. SWOT Analysis
15.3.8. Bayer AG
15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.8.2. Company Financials
15.3.8.3. Growth Strategies
15.3.8.4. SWOT Analysis
15.3.9. Eisai Co., Ltd.
15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.9.2. Company Financials
15.3.9.3. Growth Strategies
15.3.9.4. SWOT Analysis
List of Tables
Table 01: Global BCR-ABL Tyrosine Kinase Inhibitors Market Revenue (US$ Mn) Forecast, by Key Brands, 2016-2026
Table 02: Global EGFR Tyrosine Kinase Inhibitors Market Revenue (US$ Mn) Forecast, by Key Brands, 2016-2026
Table 03: Global VEGFR Tyrosine Kinase Inhibitors Market Revenue (US$ Mn) Forecast, by Key Brands, 2016-2026
Table 04: Global Other Tyrosine Kinase Inhibitors Market Revenue (US$ Mn) Forecast, by Key Brands, 2016-2026
Table 05: Patent & Market Exclusivity Overview, by Molecule (1/4)
Table 06: Patent & Market Exclusivity Overview, by Molecule (2/4)
Table 07: Patent & Market Exclusivity Overview, by Molecule (3/4)
Table 08: Patent & Market Exclusivity Overview, by Molecule (4/4)
Table 09: Global Kinase Inhibitors Market Value (US$ Mn) Forecast, by Type, 2017–2027
Table 10: Global Kinase Inhibitors Market Value (US$ Mn) Forecast, by Non-receptor Tyrosine Kinase Inhibitors, 2017–2027
Table 11: Global Kinase Inhibitors Market Value (US$ Mn) Forecast, by Receptor Tyrosine Kinase Inhibitors, 2017–2027
Table 12: Global Kinase Inhibitors Market Value (US$ Mn) Forecast, by Application, 2017–2027
Table 13: Global Kinase Inhibitors Market Value (US$ Mn) Forecast, by Oncology, 2017–2027
Table 14: Global Kinase Inhibitors Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 15: Global Kinase Inhibitors Market Value (US$ Mn) Forecast, by Region, 2017–2027
Table 16: North America Kinase Inhibitors Market Value (US$ Mn) Forecast, by Type, 2017–2027
Table 17: North America Kinase Inhibitors Market Value (US$ Mn) Forecast, by Non-receptor Tyrosine Kinase Inhibitors, 2017–2027
Table 18: North America Kinase Inhibitors Market Value (US$ Mn) Forecast, by Receptor Tyrosine Kinase Inhibitors, 2017–2027
Table 19: North America Kinase Inhibitors Market Value (US$ Mn) Forecast, by Application, 2017–2027
Table 20: North America Kinase Inhibitors Market Value (US$ Mn) Forecast, by Oncology, 2017–2027
Table 21: North America Kinase Inhibitors Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 22: North America Kinase Inhibitors Market Value (US$ Mn) Forecast, by Country, 2017–2027
Table 23: Europe Kinase Inhibitors Market Value (US$ Mn) Forecast, by Type, 2017–2027
Table 24: Europe Kinase Inhibitors Market Value (US$ Mn) Forecast, by Non-receptor Tyrosine Kinase Inhibitors, 2017–2027
Table 25: Europe Kinase Inhibitors Market Value (US$ Mn) Forecast, by Receptor Tyrosine Kinase Inhibitors, 2017–2027
Table 26: Europe Kinase Inhibitors Market Value (US$ Mn) Forecast, by Application, 2017–2027
Table 27: Europe Kinase Inhibitors Market Value (US$ Mn) Forecast, by Oncology, 2017–2027
Table 28: Europe Kinase Inhibitors Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 29: Europe Kinase Inhibitors Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 30: Asia Pacific Kinase Inhibitors Market Value (US$ Mn) Forecast, by Type, 2017–2027
Table 31: Asia Pacific Kinase Inhibitors Market Value (US$ Mn) Forecast, by Non-receptor Tyrosine Kinase Inhibitors, 2017–2027
Table 32: Asia Pacific Kinase Inhibitors Market Value (US$ Mn) Forecast, by Receptor Tyrosine Kinase Inhibitors, 2017–2027
Table 33: Asia Pacific Kinase Inhibitors Market Value (US$ Mn) Forecast, by Application, 2017–2027
Table 34: Asia Pacific Kinase Inhibitors Market Value (US$ Mn) Forecast, by Oncology, 2017–2027
Table 35: Asia Pacific Kinase Inhibitors Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 36: Asia Pacific Kinase Inhibitors Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 37: Latin America Kinase Inhibitors Market Value (US$ Mn) Forecast, by Type, 2017–2027
Table 38: Latin America Kinase Inhibitors Market Value (US$ Mn) Forecast, by Non-receptor Tyrosine Kinase Inhibitors, 2017–2027
Table 39: Latin America Kinase Inhibitors Market Value (US$ Mn) Forecast, by Receptor Tyrosine Kinase Inhibitors, 2017–2027
Table 40: Latin America Kinase Inhibitors Market Value (US$ Mn) Forecast, by Application, 2017–2027
Table 41: Latin America Kinase Inhibitors Market Value (US$ Mn) Forecast, by Oncology, 2017–2027
Table 42: Latin America Kinase Inhibitors Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 43: Latin America Kinase Inhibitors Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 44: Middle East & Africa Kinase Inhibitors Market Value (US$ Mn) Forecast, by Type, 2017–2027
Table 45: Middle East & Africa Kinase Inhibitors Market Value (US$ Mn) Forecast, by Non-receptor Tyrosine Kinase Inhibitors, 2017–2027
Table 46: Middle East & Africa Kinase Inhibitors Market Value (US$ Mn) Forecast, by Receptor Tyrosine Kinase Inhibitors, 2017–2027
Table 47: Middle East & Africa Kinase Inhibitors Market Value (US$ Mn) Forecast, by Application, 2017–2027
Table 48: Middle East & Africa Kinase Inhibitors Market Value (US$ Mn) Forecast, by Oncology, 2017–2027
Table 49: Middle East & Africa Kinase Inhibitors Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 50: Middle East & Africa Kinase Inhibitors Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
List of Figures
Figure 01: Global Kinase Inhibitors Market Value (US$ Mn) and Distribution (%), by Region, 2018 and 2027
Figure 02: Global Kinase Inhibitors Market Value (US$ Mn) Forecast, 2017–2027
Figure 03: Clinical Trial Analysis, by Phase
Figure 04: Clinical Trial Analysis, by Status
Figure 05: Global Kinase Inhibitors Market Value Share Analysis, by Type, 2018 and 2027
Figure 06: Global Kinase Inhibitors Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, by Non-receptor Tyrosine Kinase Inhibitors, 2017–2027
Figure 07: Global Kinase Inhibitors Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, by Receptor Tyrosine Kinase Inhibitors, 2017–2027
Figure 08: Global Kinase Inhibitors Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, by Multikinase inhibitors, 2017–2027
Figure 09: Global Kinase Inhibitors Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, by Serine/Threonine Kinase Inhibitors, 2017–2027
Figure 10: Global Kinase Inhibitors Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, by Protein Kinase C Inhibitors, 2017–2027
Figure 11: Global Kinase Inhibitors Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, by RHO Kinase Inhibitors, 2017–2027
Figure 12: Global Kinase Inhibitors Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, by Others, 2017–2027
Figure 13: Global Kinase Inhibitors Market Attractiveness Analysis, by Type, 2019–2027
Figure 14: Global Kinase Inhibitors Market Value Share Analysis, by Application, 2018 and 2027
Figure 15: Global Kinase Inhibitors Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, by Oncology, 2017–2027
Figure 16: Global Kinase Inhibitors Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, by Inflammatory Diseases, 2017–2027
Figure 17: Global Kinase Inhibitors Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, by Others, 2017–2027
Figure 18: Global Kinase Inhibitors Market Attractiveness Analysis, by Application, 2019–2027
Figure 19: Global Kinase Inhibitors Market Value Share Analysis, by Distribution Channel, 2018 and 2027
Figure 20: Global Kinase Inhibitors Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, by Independent Pharmacies, 2017–2027
Figure 21: Global Kinase Inhibitors Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, by Hospital Pharmacies, 2017–2027
Figure 22: Global Kinase Inhibitors Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, by Online Pharmacies, 2017–2027
Figure 23: Global Kinase Inhibitors Market Attractiveness Analysis, by Distribution Channel, 2019–2027
Figure 24: Global Kinase Inhibitors Market Value Share Analysis, by Region, 2018 and 2027
Figure 25: Global Kinase Inhibitors Market Attractiveness Analysis, by Region, 2019–2027
Figure 26: North America Kinase Inhibitors Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027
Figure 27: North America Kinase Inhibitors Market Value Share Analysis, by Type, 2018 and 2027
Figure 28: North America Kinase Inhibitors Market Attractiveness Analysis, by Type, 2019–2027
Figure 29: North America Kinase Inhibitors Market Value Share Analysis, by Application, 2018 and 2027
Figure 30: North America Kinase Inhibitors Market Attractiveness Analysis, by Application, 2019–2027
Figure 31: North America Kinase Inhibitors Market Value Share Analysis, by Distribution Channel, 2018 and 2027
Figure 32: North America Kinase Inhibitors Market Attractiveness Analysis, by Distribution Channel, 2019–2027
Figure 33: North America Kinase Inhibitors Market Value Share Analysis, by Country, 2018 and 2027
Figure 34: North America Kinase Inhibitors Market Attractiveness Analysis, by Country, 2019–2027
Figure 35: Europe Kinase Inhibitors Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027
Figure 36: Europe Kinase Inhibitors Market Value Share Analysis, by Type, 2018 and 2027
Figure 37: Europe Kinase Inhibitors Market Attractiveness Analysis, by Type, 2019–2027
Figure 38: Europe Kinase Inhibitors Market Value Share Analysis, by Application, 2018 and 2027
Figure 39: Europe Kinase Inhibitors Market Attractiveness Analysis, by Application, 2019–2027
Figure 40: Europe Kinase Inhibitors Market Value Share Analysis, by Distribution Channel, 2018 and 2027
Figure 41: Europe Kinase Inhibitors Market Attractiveness Analysis, by Distribution Channel, 2019–2027
Figure 42: Europe Kinase Inhibitors Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
Figure 43: Europe Kinase Inhibitors Market Attractiveness Analysis, by Country/Sub-region, 2019–2027
Figure 44: Asia Pacific Kinase Inhibitors Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027
Figure 45: Asia Pacific Kinase Inhibitors Market Value Share Analysis, by Type, 2018 and 2027
Figure 46: Asia Pacific Kinase Inhibitors Market Attractiveness Analysis, by Type, 2019–2027
Figure 47: Asia Pacific Kinase Inhibitors Market Value Share Analysis, by Application, 2018 and 2027
Figure 48: Asia Pacific Kinase Inhibitors Market Attractiveness Analysis, by Application, 2019–2027
Figure 49: Asia Pacific Kinase Inhibitors Market Value Share Analysis, by Distribution Channel, 2018 and 2027
Figure 50: Asia Pacific Kinase Inhibitors Market Attractiveness Analysis, by Distribution Channel, 2019–2027
Figure 51: Asia Pacific Kinase Inhibitors Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
Figure 52: Asia Pacific Kinase Inhibitors Market Attractiveness Analysis, by Country/Sub-region, 2019–2027
Figure 53: Latin America Kinase Inhibitors Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027
Figure 54: Latin America Kinase Inhibitors Market Value Share Analysis, by Type, 2018 and 2027
Figure 55: Latin America Kinase Inhibitors Market Attractiveness Analysis, by Type, 2019–2027
Figure 56: Latin America Kinase Inhibitors Market Value Share Analysis, by Application, 2018 and 2027
Figure 57: Latin America Kinase Inhibitors Market Attractiveness Analysis, by Application, 2019–2027
Figure 58: Latin America Kinase Inhibitors Market Value Share Analysis, by Distribution Channel, 2018 and 2027
Figure 59: Latin America Kinase Inhibitors Market Attractiveness Analysis, by Distribution Channel, 2019–2027
Figure 60: Latin America Kinase Inhibitors Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
Figure 61: Latin America Kinase Inhibitors Market Attractiveness Analysis, by Country/Sub-region, 2019–2027
Figure 62: Middle East & Africa Kinase Inhibitors Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027
Figure 63: Middle East & Africa Kinase Inhibitors Market Value Share Analysis, by Type, 2018 and 2027
Figure 64: Middle East & Africa Kinase Inhibitors Market Attractiveness Analysis, by Type, 2019–2027
Figure 65: Middle East & Africa Kinase Inhibitors Market Value Share Analysis, by Application, 2018 and 2027
Figure 66: Middle East & Africa Kinase Inhibitors Market Attractiveness Analysis, by Application, 2019–2027
Figure 67: Middle East & Africa Kinase Inhibitors Market Value Share Analysis, by Distribution Channel, 2018 and 2027
Figure 68: Middle East & Africa Kinase Inhibitors Market Attractiveness Analysis, by Distribution Channel, 2019–2027
Figure 69: Middle East & Africa Kinase Inhibitors Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
Figure 70: Middle East & Africa Kinase Inhibitors Market Attractiveness Analysis, by Country/Sub-region, 2019–2027
Figure 71: Global Kinase Inhibitors Market Share, by Company, 2018
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Kinase Inhibitors Market
